Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
(Date:7/24/2014)... A research team led by group leader Yung-Eun ... technology to synthesize sulfur-doped and nitrogen-doped graphenes which ... secondary batteries and fuel cells. Yung-Eun Sung is ... Nanoparticle Research at Institute for Basic Science* (IBS) ... , This achievement has great significance with regards ...
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... development and use of devices that are one-billionth of ... as a science, and the term now describes many ... than 1,000 nanometers of the substances involved in the ... the creation of exciting and innovative new products and ...
... an electronic newsletter is like giving out your phone number ... what you want. Sometimes you never hear from them again. ... are the blind date from hell. You are deluged by ... highlighting how wonderful, fast, reliable, and inexpensive their products are. ...
... with these three words, after all that has happened this ... the importance of being current with ones network security and ... came via the blaster worm, which took advantage of those ... Following closely on its heels were Sobig, Nacha, and Welchia. ...
Cached Biology Technology:Nanotechnology - Natures Lego Blocks! 2Quantity versus Quality: Effective E-Marketing Relationships 2Quantity versus Quality: Effective E-Marketing Relationships 3
(Date:7/24/2014)... over a 35 year period in which the human ... humans on declining animal numbers. This decline matters because ... crustaceans, slugs and worms bring to our day-to-day lives, ... nutrient cycling, water filtration and human health. , The ... UCL, Stanford and UCSB, focused on the demise of ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Creating sustainable STEM teacher preparation programs 2
... a widespread assumption, global warming is unlikely to expand the ... factors that are at work to corral the disease. ... of Florida researchers in a paper set to appear May ... public policy makers have been concerned that warming temperatures would ...
... satellite swept over the Gulf of Mexico oil spill from ... Spectroradiometer instrument captured sunglints in a visible image of the ... sunglint within the area of the gray-beige colored spill. Sunglint ... surface. In calm waters, the rounded image of the sun ...
... release is available in Spanish . , ... bioGUNE, in collaboration with the Universidad de Kentucky (USA), have ... types of prions (the pathogen agents responsible for transmissible spongiform ... gives the opportunity to control prion disease in deer, which ...
Cached Biology News:Scientists: Malaria control to overcome disease’s spread as climate warms 2Researchers embark on work to control the prion epidemic affecting deer in the USA 2Researchers embark on work to control the prion epidemic affecting deer in the USA 3
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: